News

Stephanie Fradette, PharmD, SVP, Head of Rare Neurology Development Unit at Biogen, gave commentary on the FDA designation and long-term outlook for salanersen, an investigational antisense agent for spinal muscular atrophy.

ProMIS Neurosciences reported no cases of ARIA-E in a six-month blinded interim analysis of PMN310, an oligomer-selective antibody in the phase 1b PRECISE-AD trial for Alzheimer disease, alongside early biomarker signals consistent with target engagement.

Carrie Hersh, DO, MSc, FAAN, president of the Consortium of Multiple Sclerosis Centers, discussed key sessions presented on disability progression, emerging biomarkers, and the shift toward comprehensive, patient-centered MS care.

Phase 1b data published in Nature Medicine and presented at AAIC 2026 showed target engagement and reductions in select cerebrospinal fluid biomarkers of neuronal and synaptic injury with the investigational anti-PD-L1 antibody.

Ahmed Obeidat, MD, PhD, associate professor of neurology at the Medical College of Wisconsin, talked about the need to rethink multiple sclerosis clinical trial design by recognizing immune cells’ potential neuroprotective roles.

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.

The Trojanowski Professor for Neurodegenerative Disease Research at the University of Pennsylvania, discusses how postmortem and longitudinal imaging findings provide new insights into the potential downstream effects of amyloid clearance on tau pathology and neurodegeneration in Alzheimer disease. [WATCH TIME: 3 Mintutes]

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC, director of the multiple sclerosis research unit at Ottawa Hospital, outlined how research-integrated multiple sclerosis care can refine treatment strategies in clinical practice.

Postmortem analyses of 8 individuals with SOD1-ALS who received tofersen showed widespread drug distribution across somatic motor system tissues and reductions of up to 84% in lumbar spinal cord SOD1 protein levels.

Here's some of what is coming soon to NeurologyLive® this week.

The professor of neurosciences and head of neuropsychology at Fleni Institute in Buenos Aires, Argentina, discussed findings from the LatAm-FINGERS study that suggest structured, multidomain lifestyle interventions may offer meaningful cognitive benefits among older adults in Latin America. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is tau-targeting therapies for Alzheimer disease!

A 12-week, placebo-controlled phase 2 trial found that an oral THC/CBD combination significantly reduced agitation in hospice-eligible patients with Alzheimer disease and other dementias, meeting its primary and key secondary endpoints.

Joey English, MD, Chief Medical Officer of Route 92 Medical, discusses the company's reperfusion platform, the goals of the SUMMIT RISE real-world evidence study, and what vessel-matched catheter technology could mean for acute ischemic stroke care.

Neurology News Network for the week ending July 26th, 2026. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 24, 2026.

Yogesh Shah, MD, explains the biological basis of P-tau217 and why blood-based biomarker testing is emerging as a practical, highly accurate tool for identifying Alzheimer's pathology.

Andrew Lee, MD, PhD, cofounder and CEO of Spot Biosystems, discusses the company's extracellular vesicle platform, the first non-viral delivery of full-length dystrophin in patients with Duchenne muscular dystrophy.

Epilepsy expert Susan Duberstein, MD, explores how multidisciplinary neurocutaneous clinics improve diagnosis, surveillance, care coordination, and long-term outcomes for patients with complex neurocutaneous syndromes.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Craig A. Erickson, MD. [LISTEN TIME: 23 minutes]

Stephen Williams, PhD, chief scientific officer of Alamar Biosciences, discusses the potential of eMTBR-tau measurement, multiplex biomarker testing, and AI-driven approaches to improve the characterization of Alzheimer disease and its coexisting pathologies.

The submission is backed by phase 3 FoCus trial data showing ALXN1840 tripled copper mobilization and produced significant, sustained neurologic improvement compared with standard of care over 48 weeks.

Kristen Harris, MD, Medical Director of the Extended Recovery Unit at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed new findings on functional recovery and community discharge rates in acquired brain injury patients undergoing skilled nursing facility rehabilitation.

At AAIC 2026, the head of sciences at the Alzheimer Center Amsterdam, discusses the growing role of biomarkers in understanding the biological complexity of Alzheimer disease and advancing more personalized approaches to diagnosis and treatment. [WATCH TIME: 3 minutes]

Spinogenix’s codabakalner, an investigational BK channel modulator, is currently being evaluated in CLARITY, a phase 2b/3 trial for the treatment of patients with Fragile X syndrome.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

A look at where things stand for Fragile X syndrome drug development, covering seven agents across four mechanisms as the field regroups from two recent Phase 3 setbacks.

In honor of Fragile X Syndrome Awareness Day, held annually on July 22, the professor of psychiatry at Cincinnati Children's Hospital outlined where testing for the disorder still falls short. [WATCH TIME: 6 minutes]